TABLE 4.
Safety outcomes in the meta‐analysis
| No. of studies | LogRR | 95%CI | p value | |
|---|---|---|---|---|
| Complications | ||||
| Deaths | 5 | –1.08 | –2.59–0.43 | 0.16 |
| Myocardial infarctions | 5 | 0.28 | –1.37–1.92 | 0.74 |
| Recurrent strokes | 5 | 0.26 | –1.39–1.91 | 0.75 |
| Hernia | 5 | –0.97 | –2.02–0.07 | 0.07 |
| Hemorrhage of the digestive tract | 5 | –0.72 | –2.00–0.56 | 0.27 |
| Hemorrhagic transformation at 24 h | 2 | 0.94 | –0.20–2.08 | 0.11 |
| Fever (>38°C) | 4 | –0.09 | –0.89–0.71 | 0.82 |
| Event | ||||
| All events | ||||
| At least one adverse event | 3 | –0.12 | –0.85–0.61 | 0.75 |
| Any serious adverse event | 4 | –0.06 | –1.99–1.87 | 0.95 |
| Frequent or special interest adverse events | ||||
| Lung infection | 5 | 0.06 | –0.58–0.69 | 0.86 |
| Urinary tract infection | 5 | 0.02 | –0.95–0.99 | 0.97 |
| Abnormal laboratory liver function test | 3 | –0.04 | –2.26–2.18 | 0.97 |
| Gastrointestinal disorders | 3 | –0.04 | –2.26–2.18 | 0.97 |
| Herpes virus infection | 4 | –0.03 | –1.96–1.90 | 0.98 |
| Arrhythmia | 3 | 0.67 | –1.33–2.66 | 0.51 |
| Macular edema | 3 | –0.04 | –2.26–2.18 | 0.97 |
Abbreviations: RR, relative risk; CI, confidence interval.